Summary Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events associated with ramucirumab therapy. Recent studies looked at the quantification of the risk of hypertension in patients receiving other anti-angiogenesis medications. We conducted a meta-analysis of randomized clinical trials with the aim to investigate the incidence and quantify the risk of new-onset hypertension of any grade in patients treated with ramucirumab. Our research suggests that hypertension is frequently associated with ramucirumab therapy, with an OR of 3.60 for any grade of hypertension and an even stronger correlation with grade 3-4 hypertension (OR 4.16). These data suggest that a strict monitoring, as well as early intervention protocols, are recommended in patients receiving the drug.
Introduction
Angiogenesis is considered one of the hallmarks of tumour growth and metastatic dissemination. The angiogenesis process is regulated by multiple molecular systems. One of the most potent signals involved in angiogenesis is mediated by the vascular endothelial growth factor (VEGF and related isoforms) and its receptors (VEGFR 1 and 2). Members of this family of proteins are involved in new vessel formation within the tumour. Nowadays it is possible to modulate VEGF-VEGFR interactions in many pathological conditions using anti-VEGF targeted therapy [1] . Ramucirumab is a human IgG1 monoclonal antibody against VEGFR-2 and prevents ligand binding and receptor-mediated pathway activation in endothelial cells [2] . In 2014, on the basis of the data obtained from two phase III trials [3] [4] [5] the U. S. Food and Drug Administration (FDA) approved ramucirumab, as a single agent, for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma whose disease has progressed on or after prior treatment with fluoropyrimidine-or platinum-containing chemotherapy. Ramucirumab was also approved in combination with FOLFIRI for the treatment of patients with metastatic nonsmall cell lung cancer (NSCLC) [6] , as well as of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on first line bevacizumab-, oxaliplatin-and fluoropyrimidine-containing regimens [7] and on the other hand, a phase III study failed to show efficacy of ramucirumab therapy as second line treatment of advanced hepatocellular carcinoma [8] . Currently, an ongoing phase III is evaluating the safety and efficacy of ramucirumab in combination with Electronic supplementary material The online version of this article (doi:10.1007/s10637-017-0452-1) contains supplementary material, which is available to authorized users. docetaxel in participants with urothelial cancer who failed prior platinum-based therapy (NCT02426125).
As expected from an anti-angiogenic agent, hypertension represents a frequent adverse event recorded during treatment with ramucirumab. However, the overall incidence and risk of hypertension caused by ramucirumab is yet to be well defined, due to the limited number of studies available, the variation of the results reported in each of these trials, as well as the differences in study-settings and tumour-stream. Furthermore, hypertension events should be monitored as poor management may lead to serious cardiovascular events, dose reduction or discontinuation of anti-cancer therapies, or even lifethreatening consequences. Therefore, the aim of this review is to perform a pooled analysis based on all the data available in the literature on new-onset, ramucirumab-related hypertension.
Materials and methods

Data retrieval strategies
We conducted this meta-analysis of randomized controlled trials (RCTs) in accordance with the preferred reported items for systematic reviews and meta-analysis guidelines [9] . The search criteria were limited to articles published in the English language and involving phase III or phase II randomized controlled trials. PubMed/MEDLINE and the Cochrane Library and ASCO University Meeting abstracts were searched for relevant publications using the following MeSH terms: Bramucirumab^, BVEGF-2^and Banti-angiogenic^. Publications available in these databases until September 1, 2016, were analysed. The search was restricted to human studies. The computer search was supplemented with manual searches of the references listed in all retrieved review articles, primary studies, and abstracts from meetings. When the results of a study were reported in further interim analyses, only the most recent, complete and updated version was included in our review.
Inclusion criteria
Two independent reviewers screened the studies according to specific inclusion and exclusion criteria. In the event of disagreements, a third reviewer was involved. The studies considered for the analysis were identified accordingly to the following inclusion criteria: 1) participants treated for solid tumours; 2) ramucirumab as experimental treatment; 3) the presence of a control arm for comparison, 4) outcome: assessment of the odds ratio (OR) of the adverse event Bhypertension^; both all-grade (grades 1-4) and high-grade (grades 3-4) events were considered as main outcomes. The following exclusion criteria were used: 1) insufficient availability of data estimating the outcomes; 2) animal studies; 3) sample size of each arm too small (less than 10 participants/ arm); and 4) the presence of a single arm study.
Data extraction and quality assessment
The author CP independently extracted the number of patients with hypertension. For these data, all-grade and grade 3-4 adverse events were collected separately. The methodological quality of each included RCT was assessed by two independent researchers. The study quality was assessed using the Jadad 5-item scale, considering randomisation, double blinding and withdrawals. The final score ranged from 0 to 5 [10] . Disagreements were evaluated by a kappa test, and consensus was achieved after discussion with the corresponding author (GR).
Statistical analysis
The statistical analyses were performed using Revman 5.3. The summary estimates were generated using a fixed-effect model (Mantel-Haenszel method) or a random-effects model (DerSimonian-Laird method) [11, 12] depending on the presence or absence of heterogeneity. Statistical heterogeneity was assessed using the Q-test and I 2 . I 2 values of 25%, 50% and 75% indicated low, moderate and high heterogeneity, respectively [13] . If P > 0.1 and I 2 < 50%, the fixed-effects model was used; otherwise, the random-effects model was used. The calculation of the incidence rate was performed from the data available in each study. We also calculated the OR and confidence intervals of events in patients assigned to treatment with ramucirumab compared with the controls in the same study. Subgroups stratification analyses (according to tumour site and schedule of treatment) were performed. In light of the small number of trials included, no publication bias was estimated. For all statistical analyses, a value of P < 0.05 was regarded as statistically significant, and all tests were twosided.
Results
The search yielded 4072 potentially relevant articles. Of these, 1008 studies were excluded as duplicates. After viewing the titles and abstracts of the 3064 remaining studies, the full texts of 18 studies were retrieved and 8 studies [3, 4, [6] [7] [8] [14] [15] [16] were included in the analysis (Fig. 1 supplementary data) . The characteristics of the studies included are summarized in Table 1 . The studies included 2213 cases treated with ramucirumab and 2084 cases in the control group for a total of 4297 patients. Among these studies, three studies involved gastric cancer (GC), two mCRC and NSCLC and one hepatocellular carcinoma, respectively. The incidence of any grade of hypertension ranged from 11 to 37.8% in the ramucirumab group and 0-12.5% in the control group respectively ( Table 1) . The pooled analysis with a fixed-effects model revealed that the incidence of any grade of hypertension was higher with ramucirumab (OR = 3.60, 95% CI: 2.93-4.42; P = <0.00001; Fig. 1 ) than in the control arms. Subgroup analysis according to the different tumor type revealed that the OR was higher in patients affected by GC and by mCRC (4.15 and 4.09 respectively). The incidence of grade 3-4 hypertension ranged from 6 to 15.9% in the ramucirumab group and from 0 to 4% in the control group respectively ( Table 1 ). The pooled analysis with a fixed-effects model revealed that the incidence of grade 3-4 hypertension was higher in patient treated with ramucirumab (OR = 4.16, 95% CI: 3.07-5.64; P = <0.00001; Fig. 2 ) than in the control arms. Subgroup analysis accordingly to the different tumour types revealed that the OR was higher in patients with GC and mCRC (5.07 and 4.49 respectively). Finally, OR for hypertension was higher when ramucirumab was administered in combination with doublet chemotherapy (Figs. 2,3 supplementary data) .
Discussion
Ramucirumab exerts its anti-tumour activity by inhibiting the VEGFR-2 and has been clinically validated as a targeted agent against several different tumours. Although generally easily manageable with anti-hypertensive medications, hypertension is commonly associated with ramucirumab therapy. However, the overall incidence and risk of ramucirumab-induced hypertension remains unknown due to the lack of comprehensive and systematic meta-analyses of clinical trials results. In our study, we showed an incidence of higher grades of hypertension not superior to 15% in patients exposed to a ramucirumab-based therapy. To the best of our knowledge, this is the first study defying the risk of hypertension with ramucirumab-based therapy in solid tumors. It is well known that the rates of any-grade hypertension change considerably across tumour streams. In a recent retrospective study, Fraeman et al. showed that the incidence-rate of hypertension is higher in patients with gastric and ovarian cancer [17] . Interestingly, in our analysis, the risk of hypertension from ramucirumab seems higher for patients with gastric cancer compared to other tumours (Figs. 2 and 3) . Although further studies are needed to investigate these results, a possible Fig. 2 Forest plots of Odds Ratio (OR) for grade 3-4 hypertension comparing experimental to control arm. The Chi-squared test showed absence of heterogeneity between the trials. The fixed effects model was used explanation for these findings could lay in the heterogeneous biological characteristics of each tumour stream, underlying their progression pattern and the response to specific treatments.
In accordance to the previously cited retrospective study, all-grades hypertension events appeared to be far more frequent in patients who received chemotherapy [17] . Additionally, we noted that the OR of hypertension increases when ramucirumab is given in combination with more than one chemotherapy drug, in comparison to ramucirumab monotherapy or to the combination of ramucirumab plus single agent chemotherapy (Figs. 2,3 supplementary data) .
Higher risk of drug-induced hypertension of any grade was also shown in patients who received another anti-angiogenic targeted antibody [18, 19] . Bevacizumab is a humanised monoclonal antibody that inhibits angiogenesis by neutralising circulating VEGF and it is currently approved for the treatment several malignancies. Chen et al. assessed the overall risk and incidence of hypertension in all-grade hypertension (OR: 8.07) and high-grade hypertension (OR: 5.93) with bevacizumab in NSCLC patient [18] while QU et al. found an OR of 4.982 in patient with mCRC [19] . In line with these results, ramucirumab increased the risk of hypertension, however we found a lower OR in NSCLC and mCRC.
Our analysis presents few limitations: the impact of variables such as tumour type, chosen control and patients characteristics in the analysed studies has been considered. Furthermore, other variables, such as a patients' medical history, were not well defined and different versions of the Common Terminology Criteria for Adverse Events (CTCAE) were used in the trials. Moreover, it is noteworthy that our analysis was based on the literature rather than on individual patients' data.
Angiogensis is still considered one of the main actionable targets of anticancer therapies. Here, we quantify the risk of any grade and higher grade hypertension for patients treated with ramucirumab (OR: 3.60 and 4.16 respectively). This information underlines the need for close monitoring of patients receiving ramucirumab. Further studies are needed to investigate the significance of these findings and the possibility that, as for bevacizumab, new-onset hypertension could represent clinical surrogate biomarker to predict the efficacy of ramucirumab treatment in solid cancers [20] .
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